Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy ...

25, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ ... RSV infections occur all year round, with notable peaks typically occurring ...

25, 2024 /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ ... iv Specifically in Malaysia, RSV infections occur all year round, with notable ...

And that earns it the top spot in our round of the best logo maker and designer tools. As such, this makes Wix the best logo maker for beginners (or creatives in a hurry). You can change colors ...

GlaxoSmithKline (GSK) announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia ... Specifically in Malaysia, RSV infections occur all year round, with notable peaks typically occurring ...